Like dominant negative CARD11 mutations, CARD14 mutations that attenuate NF-κB activity are associated with AD and hyper-IgE (122), whereas complete absence of CARD14 is not associated with AD (141). This evidence concerns the gene NFKB1 and Alzheimer disease.